These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 28168884)

  • 1. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
    Chung EK; Fleming MR; Cheatham SC; Kays MB
    Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
    Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
    Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
    Bhalodi AA; Keel RA; Quintiliani R; Lodise TP; Nicolau DP; Kuti JL
    Ann Pharmacother; 2013 May; 47(5):617-27. PubMed ID: 23585647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB
    J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.
    Lee DH; Kim YK; Jin K; Kang MJ; Joo YD; Kim YW; Moon YS; Shin JG; Kiem S
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.
    Rahbar AJ; Lodise TP; Abraham P; Lockwood A; Pai MP; Patka J; Rabinovich M; Curzio K; Chester K; Williams B; Morse B; Chaar M; Huang V; Salomone J
    Surg Infect (Larchmt); 2016 Dec; 17(6):675-682. PubMed ID: 27841954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
    Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
    J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
    Samtani MN; Flamm R; Kaniga K; Nandy P
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2360-4. PubMed ID: 20385857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.
    Stein GE; Kulhanek G; Smith CL; Kuti JL; Nicolau DP; Scharmen A; Farnum C; Tran M; Kalra A; Havlichek DH
    Ann Pharmacother; 2012 Oct; 46(10):1281-6. PubMed ID: 23012385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/Pharmacodynamic Analysis for Doripenem Regimens in Intensive Care Unit Patient.
    Tanaka R; Sato Y; Goto K; Yasuda N; Ohchi Y; Suzuki Y; Ueno T; Ito K; Kaneko T; Kurogi S; Nonoshita K; Itoh H
    Biol Pharm Bull; 2017; 40(8):1226-1231. PubMed ID: 28769004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
    Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight.
    Chung EK; Cheatham SC; Healy DP; Stock AH; Utley S; Campion M; Murrey T; Gesenhues AM; Jeffery J; Kays MB
    Int J Antimicrob Agents; 2023 Apr; 61(4):106751. PubMed ID: 36758780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
    Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
    Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Doripenem in Pediatric Patients and Monte-Carlo Pharmacokinetic-Pharmacodynamic Simulations for Dosing Regimen Assessment.
    Matsuo Y; Ishibashi T; Matsumoto S; Katsube T; Wajima T
    J Pharm Sci; 2019 Sep; 108(9):3099-3105. PubMed ID: 30974120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.